v3.26.1
Note 2 - Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2026
Notes Tables  
Segment Reporting [Table Text Block]
  

For the Six Months Ended June 30,

 
  

2026

  

2025

 
  

Cardiac Electrophysiology

  

Private Aviation

  

Total

  

Total

 

Revenues:

                

Product revenue

                

VIVO

 $127  $—  $127  $86 

LockeT

  391   —   391   269 

Total product revenues

  518   —   518   355 
                 

Service revenue, net

                

Luxe

  —   69   69   — 

Hops

  —   864   864   — 

Total service revenues, net

  —   933   933   — 

Total revenues

  518   933   1,451   355 
                 

Less:

                

Cost of revenues:

                

Cost of product revenue

  53   —   53   25 

Cost of service revenue

  —   910   910   — 

Total cost of revenues

  53   910   963   25 
                 

Acquired in-process research and development expense

  —   —   —   1,967 

Depreciation and amortization expense

  734   52   786   1,060 

Stock-based compensation expense

  330   —   330   189 

Salaries and benefits expense

  1,457   287   1,744   2,624 

Professional fees

  1,641   163   1,804   1,044 

Research and development expense

  291   —   291   258 

Interest income

  (6)  —   (6)  (21)

Interest expense

  277   46   323   116 

Change in fair value of royalties payable due to related parties

  —   —   —   2,830 

Change in fair value of trading debt securities

  —   —   —   (10)

Change in fair value of minority equity interest

  2,302   —   2,302   — 

Change in fair value of deferred consideration

  (3,195)  —   (3,195)  — 

Loss on debt extinguishment

  105   —   105   — 

Unrealized gains and losses, net

  (378)  —   (378)  — 

Income tax benefit

  (487)  —   (487)  (1,674)

Other segment items (1)

  1,271   594   1,865   1,450 

Segment and consolidated net loss

 $(3,877) $(1,119) $(4,996) $(9,503)
  

For the Three Months Ended June 30,

 
  

2026

  

2025

 
  

Cardiac Electrophysiology

  

Private Aviation

  

Total

  

Total

 

Revenues:

                

Product revenue

                

VIVO

 $54  $—  $54  $71 

LockeT

  216   —   216   141 

Total product revenues

  270   —   270   212 
                 

Service revenue, net

                

Luxe

  —   27   27   — 

Hops

  —   722   722   — 

Total service revenues, net

  —   749   749   — 

Total revenues

  270   749   1,019   212 
                 

Less:

                

Cost of revenues:

                

Cost of product revenue

  22   —   22   14 

Cost of service revenue

  —   899   899   — 

Total cost of revenues

  22   899   921   14 
                 

Acquired in-process research and development expense

  —   —   —   1,848 

Depreciation and amortization expense

  367   15   382   529 

Stock-based compensation expense

  266   —   266   98 

Salaries and benefits expense

  647   282   929   1,310 

Professional fees

  1,127   21   1,148   317 

Research and development expense

  142   —   142   155 

Interest income

  (4)  —   (4)  (3)

Interest expense

  174   30   204   67 

Change in fair value of royalties payable due to related parties

  —   —   —   1,667 

Change in fair value of trading debt securities

  —   —   —   (10)

Change in fair value of minority equity interest

  —   —   —   — 

Change in fair value of deferred consideration

  (318)  —   (318)  — 

Loss on debt extinguishment

  105   —   105   — 

Unrealized gains and losses, net

  (378)  —   (378)  — 

Income tax benefit

  (312)  —   (312)  (950)

Other segment items (1)

  751   489   1,240   628 

Segment and consolidated net loss

 $(2,319) $(987) $(3,306) $(5,458)
Fair Value, by Balance Sheet Grouping [Table Text Block]
      

June 30, 2026

     
  

Total

  

Level 1

  

Level 2

  

Level 3

 

Assets:

                

Cash equivalents

                

Money market funds

 $12  $12  $—  $— 

Marketable securities

  1,196   1,196   —   — 

Total assets

 $1,208  $1,208  $—  $— 
                 

Liabilities:

                

Royalties payable due to related parties

 $792  $—  $—  $792 

Deferred stock issuance liability

  647   —   —   647 

Total liabilities

 $1,439  $—  $—  $1,439 
      

December 31, 2025

     
  

Total

  

Level 1

  

Level 2

  

Level 3

 

Assets:

                

Cash Equivalents

                

Money market funds

 $2  $2  $—  $— 

Total assets

 $2  $2  $—  $— 
                 

Liabilities:

                

Royalties payable due to related parties

 $792  $—  $—  $792 

Convertible notes payable

  298   —   —   298 

Total liabilities

 $1,090  $—  $—  $1,090 
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
  

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

 
  

Royalties Payable due to Related Parties

  

Deferred Stock Issuance Liability

  

Deferred Consideration

  

Convertible Notes Payable

 

Balance at January 1, 2026

 $792  $—  $—  $298 

Fair value at issuance

  —   —   11,028   — 

Change in fair value

  —   —   (2,877)  — 

Balance at March 31, 2026

  792   —   8,151   298 

Fair value at issuance

  —   601   —   — 

Change in fair value

  —   46   (318)  — 

Settlement of financial instruments

  —   —   (7,833)  (403)

Realized (gains) and losses

  —   —   —   105 

Balance at June 30, 2026

 $792  $647  $—  $— 
  Fair Value Measurements Using Significant Unobservable Inputs (Level 3) 
  

Royalties Payable due to Related Parties

  

Trading Debt Securities

 

Balance at January 1, 2025

 $9,213  $— 

Change in fair value

  1,163   — 

Balance at March 31, 2025

  10,376   — 

Purchased

  —   864 

Change in fair value

  1,667   10 

Balance at June 30, 2025

 $12,043  $874 
Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]

Machinery and equipment

  2 - 5 years 

Computer hardware and software

  1 - 5 years 

LockeT animation video

  3 years 

VIVO DEMO/Clinical Systems

  1-5 years 
Disaggregation of Revenue [Table Text Block]
  

For the Three Months Ended June 30,

  

For the Six Months Ended June 30,

 
  

2026

  

2025

  

2026

  

2025

 

Product Revenue

                

US

 $210  $173  $364  $308 

Europe

  60   39   154   47 

Total Product Revenue

 $270  $212  $518  $355 
                 

Service Revenue

                

US

 $749  $—  $933  $— 

Europe

  —   —   —   — 

Total Service Revenue

 $749  $—  $933  $— 
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
  

Six Months Ended June 30,

 
  

2026

  

2025

 

Deferred revenue, beginning of period

 $—  $— 

Deferred revenue assumed as part of acquisition (see Note 3)

  171   — 

Revenue recognized during the period related to amounts included in the deferred revenue assumed

  (191)  — 

Revenue deferred, net of revenue recognized during the period

  165   — 

Deferred revenue, end of period

 $145  $— 
Royalties Payable [Member]  
Notes Tables  
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

Instrument

Valuation Technique

Unobservable Input

 

Input Range

 

Royalties payable due to related parties

Discounted future cash flows

Revenue adjusted discount rate

  19.5%

Deferred stock issuance liability

If converted method

Discount for lack of marketability

  20%